Cowanna, MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 16th...

Cowanna,
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 16th November 2020: Alterity Therapeutics (ASX:
ATH, NASDAQ: ATHE) (“Alterity” or “the Company”) has today announced the allowance of a new
composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent
is the product of in-house discovery research and is central to Alterity’s next generation drug development
portfolio focussed on neurodegenerative diseases.
The patent, entitled “Compounds for and Methods of Treating Diseases” (Application No. 16/818,641),
covers more than 150 novel pharmaceutical compositions that are designed to redistribute the labile
iron implicated in Parkinson’s disease, Alzheimer’s disease and other neurodegenerative conditions. The
patent, which was filed in March of 2020, underwent prioritized examination by the USPTO.

We do not know anything about these 150 compositions but it is "central to Alterity's next generation drug development". So there are possibilities to find one drug after this PBT2 coming to the market most likely this year (?).